Mattea Reinisch

4.3k total citations
63 papers, 762 citations indexed

About

Mattea Reinisch is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mattea Reinisch has authored 63 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 31 papers in Cancer Research and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mattea Reinisch's work include Breast Cancer Treatment Studies (30 papers), Advanced Breast Cancer Therapies (20 papers) and HER2/EGFR in Cancer Research (19 papers). Mattea Reinisch is often cited by papers focused on Breast Cancer Treatment Studies (30 papers), Advanced Breast Cancer Therapies (20 papers) and HER2/EGFR in Cancer Research (19 papers). Mattea Reinisch collaborates with scholars based in Germany, Switzerland and United States. Mattea Reinisch's co-authors include Sherko Kümmel, I. Theuerkauf, Enrico Pelz, Sibylle Loibl, Beyhan Ataseven, Gϋnter von Minckwitz, Carsten Denkert, Michael Untch, Valentina Nekljudova and Jens‐Uwe Blohmer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Mattea Reinisch

59 papers receiving 751 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mattea Reinisch Germany	17	431	251	222	158	101	63	762
Sandra S. Hatch United States	16	324 0.8×	383 1.5×	127 0.6×	224 1.4×	54 0.5×	55	829
Taner Babacan Türkiye	15	409 0.9×	217 0.9×	136 0.6×	142 0.9×	34 0.3×	52	788
Ken Uchida Japan	14	228 0.5×	153 0.6×	112 0.5×	141 0.9×	76 0.8×	44	581
Jihyoung Cho South Korea	14	225 0.5×	353 1.4×	82 0.4×	274 1.7×	61 0.6×	52	752
Christelle Fauré France	10	475 1.1×	214 0.9×	51 0.2×	183 1.2×	78 0.8×	20	900
Mustafa Tükenmez Türkiye	11	181 0.4×	183 0.7×	69 0.3×	169 1.1×	57 0.6×	50	468
Christina A. Dilaveri United States	8	179 0.4×	205 0.8×	55 0.2×	116 0.7×	52 0.5×	17	409
Chizuko Kanbayashi Japan	12	355 0.8×	179 0.7×	275 1.2×	76 0.5×	18 0.2×	36	593
Amanda L. Kong United States	14	322 0.7×	413 1.6×	65 0.3×	253 1.6×	34 0.3×	71	890
Annamaria Molino Italy	17	516 1.2×	348 1.4×	106 0.5×	125 0.8×	17 0.2×	38	875

Countries citing papers authored by Mattea Reinisch

Since Specialization

Citations

This map shows the geographic impact of Mattea Reinisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mattea Reinisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mattea Reinisch more than expected).

Fields of papers citing papers by Mattea Reinisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mattea Reinisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mattea Reinisch. The network helps show where Mattea Reinisch may publish in the future.

Co-authorship network of co-authors of Mattea Reinisch

This figure shows the co-authorship network connecting the top 25 collaborators of Mattea Reinisch. A scholar is included among the top collaborators of Mattea Reinisch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mattea Reinisch. Mattea Reinisch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loibl, S., Michael Untch, Jens Huober, et al.. (2025). 292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial. Annals of Oncology. 36. S303–S304. 1 indexed citations

Graeser, Monika, Oleg Gluz, Peter Schmid, et al.. (2024). Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.. Journal of Clinical Oncology. 42(16_suppl). 590–590. 1 indexed citations

Kümmel, Sherko, Christoph Wallner, Johannes Maximilian Wagner, et al.. (2023). The Partner Perspective on Autologous and Implant-Based Breast Reconstruction. Aesthetic Plastic Surgery. 47(4). 1324–1331. 4 indexed citations

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treatment Reviews. 121. 102631–102631. 6 indexed citations

Jérusalem, Guy, Aleix Prat, Roberto Salgado, et al.. (2023). Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. The Breast. 72. 103580–103580. 23 indexed citations

Reinisch, Mattea, Jens‐Uwe Blohmer, Theresa Link, et al.. (2022). 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Annals of Oncology. 33. S166–S167. 1 indexed citations

Wallner, Christoph, Paolo Montemurro, Sherko Kümmel, et al.. (2022). The Search for the Ideal Female Breast: A Nationally Representative United-States-Census Study. Aesthetic Plastic Surgery. 46(4). 1567–1574. 12 indexed citations

Reinisch, Mattea, et al.. (2021). Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers. Orphanet Journal of Rare Diseases. 16(1). 363–363. 3 indexed citations

Haller, Heidemarie, Gustav Dobos, Mattea Reinisch, et al.. (2021). Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial. Cancers. 13(16). 4082–4082. 35 indexed citations

10.

Breit, Elisabeth, et al.. (2021). Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. Cancers. 13(18). 4564–4564. 9 indexed citations

11.

Schmutzler, Rita K., et al.. (2020). Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. npj Breast Cancer. 6(1). 31–31. 16 indexed citations

12.

Miles, D.W., Joseph Gligorov, Fabrice André, et al.. (2020). LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology. 31. S1147–S1148. 74 indexed citations

13.

Reinisch, Mattea, Michael Untch, Toralf Reimer, et al.. (2020). 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Annals of Oncology. 31. S44–S44. 1 indexed citations

14.

Ataseven, Beyhan, Philipp Harter, Alexander Traut, et al.. (2019). Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial. Supportive Care in Cancer. 28(8). 3605–3615. 16 indexed citations

15.

Reinisch, Mattea, et al.. (2018). Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice. Breast Care. 13(2). 114–118. 14 indexed citations

16.

Kümmel, Sherko, et al.. (2018). Jumping Breast Phenomenon Following Subcutaneous Mastectomy: First Description and Grading of a Well-Known Breast Deformity. Breast Care. 13(5). 354–358. 7 indexed citations

17.

Kümmel, Sherko, Jens‐Uwe Blohmer, Andreé Faridi, et al.. (2018). Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPRÄC. Breast Care. 14(3). 165–169. 1 indexed citations

18.

Reinisch, Mattea, Oleg Gluz, Beyhan Ataseven, et al.. (2018). Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients. Breast Care. 14(3). 159–164. 2 indexed citations

19.

Reinisch, Mattea, Sabine Seiler, Sabine Schmatloch, et al.. (2018). Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Annals of Oncology. 29. viii706–viii706. 3 indexed citations

20.

Ignatov, Atanas, et al.. (2017). A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study. Journal of Cancer Research and Clinical Oncology. 144(2). 381–387. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact